Effects of erythropoietin on mobilisation of haemopoietic progenitor cells.

2.50
Hdl Handle:
http://hdl.handle.net/10541/97389
Title:
Effects of erythropoietin on mobilisation of haemopoietic progenitor cells.
Authors:
Pettengell, Ruth; Woll, Penella J; Chang, James; Coutinho, Lucia H; Testa, Nydia G; Crowther, Derek
Abstract:
Peripheral blood progenitor cell (PBPC) mobilising regimens that do not include cytotoxic drugs are needed if PBPC are to be used for allogeneic transplantation. We have studied the effects of erythropoietin on bone marrow and circulating haemopoietic progenitors. Eleven patients with untreated lymphoma received epoetin-alpha 300 or 450 iu/kg subcutaneously (sc) thrice weekly for 2 weeks. Their bone marrows and peripheral bloods were normal at entry. There were no differences between dose levels. Peripheral blood colony-forming cell (CFC) numbers increased fivefold over baseline (p = 0.003) including a sevenfold increase in GM-CFC (p = 0.003). CD34-positive cell numbers increased 4.6-fold (P < 0.01). Maximal CFC release was seen at days 5-8. No consistent change in megakaryocyte numbers was seen. The increase in numbers of cells capable of long-term haemopoiesis was not significant. The ratio of myeloid:erythroid cells in bone marrow reduced from 2.7 to 0.86 after erythropoietin treatment (p = 0.047). In bone marrow the only significant rise in CFCs was in erythroid progenitors. Erythropoietin alone resulted in a modest increase in PBPC that is unlikely to be useful for transplantation. The effects of erythropoietin in combination with other cytokines or with cytotoxic drugs remain to be explored.
Affiliation:
Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
Effects of erythropoietin on mobilisation of haemopoietic progenitor cells. 1994, 14 (1):125-30 Bone Marrow Transplant.
Journal:
Bone Marrow Transplantation
Issue Date:
Jul-1994
URI:
http://hdl.handle.net/10541/97389
PubMed ID:
7951099
Type:
Article
Language:
en
ISSN:
0268-3369
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorPettengell, Ruthen
dc.contributor.authorWoll, Penella Jen
dc.contributor.authorChang, Jamesen
dc.contributor.authorCoutinho, Lucia Hen
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-04-26T13:26:30Z-
dc.date.available2010-04-26T13:26:30Z-
dc.date.issued1994-07-
dc.identifier.citationEffects of erythropoietin on mobilisation of haemopoietic progenitor cells. 1994, 14 (1):125-30 Bone Marrow Transplant.en
dc.identifier.issn0268-3369-
dc.identifier.pmid7951099-
dc.identifier.urihttp://hdl.handle.net/10541/97389-
dc.description.abstractPeripheral blood progenitor cell (PBPC) mobilising regimens that do not include cytotoxic drugs are needed if PBPC are to be used for allogeneic transplantation. We have studied the effects of erythropoietin on bone marrow and circulating haemopoietic progenitors. Eleven patients with untreated lymphoma received epoetin-alpha 300 or 450 iu/kg subcutaneously (sc) thrice weekly for 2 weeks. Their bone marrows and peripheral bloods were normal at entry. There were no differences between dose levels. Peripheral blood colony-forming cell (CFC) numbers increased fivefold over baseline (p = 0.003) including a sevenfold increase in GM-CFC (p = 0.003). CD34-positive cell numbers increased 4.6-fold (P < 0.01). Maximal CFC release was seen at days 5-8. No consistent change in megakaryocyte numbers was seen. The increase in numbers of cells capable of long-term haemopoiesis was not significant. The ratio of myeloid:erythroid cells in bone marrow reduced from 2.7 to 0.86 after erythropoietin treatment (p = 0.047). In bone marrow the only significant rise in CFCs was in erythroid progenitors. Erythropoietin alone resulted in a modest increase in PBPC that is unlikely to be useful for transplantation. The effects of erythropoietin in combination with other cytokines or with cytotoxic drugs remain to be explored.en
dc.language.isoenen
dc.subjectHaematopoiesisen
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subjectHaematopoietic Stem Cellsen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshBone Marrow-
dc.subject.meshColony-Forming Units Assay-
dc.subject.meshErythropoietin-
dc.subject.meshFemale-
dc.subject.meshHematopoiesis-
dc.subject.meshHematopoietic Stem Cell Transplantation-
dc.subject.meshHematopoietic Stem Cells-
dc.subject.meshHodgkin Disease-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshRecombinant Proteins-
dc.subject.meshTransplantation, Autologous-
dc.titleEffects of erythropoietin on mobilisation of haemopoietic progenitor cells.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalBone Marrow Transplantationen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.